Onco-Summaries: Daily Oncology Updates at a Glance

23/11/2025

NovelWise's NBM-BMX received the FDA orphan drug designation for uveal melanoma (Ref)

The US FDA granted the orphan drug designation to NovelWise Pharmaceutical Corporation's NBM-BMX (selective HDAC8 inhibitor) for the treatment of uveal melanoma.

• John Soong, MD, Chief Executive Officer, NovelWise: “Receiving both Fast Track Designation and now Orphan Drug Designation underscores NBM-BMX’s promise in addressing a high unmet medical need for patients with uveal melanoma. These regulatory milestones will accelerate the development pathway for NBM-BMX and support our mission of delivering innovative therapy options to patients suffering from rare and aggressive cancers.”